Bonus BioGroup Secures Exclusivity in the U.S. over Manufacturing and Commercialization of Live Bone Graft


The approval of a U.S. Patent grants the Company exclusivity over manufacturing and commercialization of live bone graft....


For the first time ever, bone graft grown outside patient's body is implanted in his leg, in an orthopedic clinical...


an Israeli biotechnology company engaged in personalized tissue engineering and cell therapy, and developing proprietary technology for growing live human bone grafts for implant in human patients...

One Week Following Receipt of Required Approvals for Second Clinical Trial


Bonus BioGroup announces today enrolment of three subjects in its second clinical trial for the repair of maxillofacial bone loss.


Bonus BioGroup Expands Prospective Product Line


Bonus BioGroup announces today successful results of a preclinical feasibility study on developing a large single-unit vascularized (blood vessel-containing) live human bone graft that can be ...

Bonus BioGroup Raises 4 Million NIS at 70 Agorot per Share


Fundraised a total of 18 million NIS at a price 18% higher than the average stock exchange and intends to register all of its shares for trade in the US, at the NASDAQ or NYSE.


Bonus BioGroup Receives Israeli Ministry of Health Approval for Clinical Trial Testing Second Generation Injectable Human Bone Graft for Maxillofacial Repair


Bonus BioGroup announces Israeli Ministry of Health approval to carry out a clinical trial with its second-generation injectable human bone graft for the repair of maxillofacial bone loss.

Bonus BioGroup Enters Into an Exclusive Agreement for the Use of Engineered Nanoparticle Technology to Enhance Bone Regeneration


Bonus BioGroup announces today that on December 3, 2015, Bonus Therapeutics Ltd, a wholly owned subsidiary of the Company, signed an agreement with the Bar-Ilan Research and Development Company Ltd.


Bonus BioGroup to Hold Pre-IND Meeting with FDA Focused on Proposed Clinical Trial in the US


Bonus BioGroup reports a Pre-IND (Preliminary Investigational New Drug) meeting to be held in December 2015 with the Food and Drug Administration (FDA) in order to discuss the development of the Company's live human bone graft as treatment for craniomaxillofacial bone deficiencies.

Bonus BioGroup Raises Investment of 5.2 Million NIS through Private Offering at 60 Cents per Share


On November 6, 2015, Bonus BioGroup entered into investment agreements with two foreign investors. Under the terms of the investment agreements, the Company will issue, in a private allocation, a joint total of 8,710,000 common shares without nominal value, registered to the Company, against cash payment of 1.34 million USD.


Bonus BioGroup Announces Chief Scientist Support of R&D Program totalling 6.4 million NIS


Bonus BioGroup announces that on July 12, 2015, Bonus Therapeutics Ltd., a fully-owned subsidiary of the Company, was approved a grant by the Israeli Chief Scientist to support its R&D program for 2015. The support amounts to 6.4 million NIS - and reflects a 60% increase in the company`s annual R&D budget over the previous year.

Bonus BioGroup Receives EU Grant for Joint Development of New Method for Graft Tracking In Vivo.


Bonus BioGroup announces that its subsidiary, Bonus Therapeutics Ltd, will receive its first EU grant, together with European research collaborators, to develop a non-invasive method for tracking in vivo (in the living body) the biological activity of its proprietary human live bone graft following transplantation.


Bonus BioGroup Announces Agreement to Develop Innovative Biological Components


The agreement allows Bonus to receive FDA approval for innovative biological components which will be integrated into its manufactured transplants. These will be submitted to the FDA at no cost for Bonus.

Bonus Therapeutics selected amongst 100 most promising innovative Technology companies in Europe


Bonus BioGroup is proud to announce that it was notified that Bonus Therapeutics Ltd., a wholly owned subsidiary of the Company, has been selected as a finalist for the 2015 edition of Red Herrings Top 100 Europe Award.


Bonus BioGroup Has Completed the Recruitment of 20 Patients for the Human Facial Bone Deficiency Treatment Clinical Trial


Bonus BioGroup announced today that it was notified by the investigator at the medical center of the accomplishment of 20 patients recruitment. This is the maximal number approved for the human facial bone deficiency treatment clinical trial, using live human bone grafts.

Bonus BioGroup Announces Receiving European GMP and International ISO-9001 Certification


Bonus is pleased to announce today that SWINET  Swiss Institute for Inspection, Education and Training  an EMA (European Medicines Agency) recognized Institute for inspection and accreditation, certified Bonus BioGroup